Beginning July 1, millions of Medicare beneficiaries will gain access to popular weight-loss medications at a fraction of their usual cost through a new federal pilot program, but medical experts caution that price shouldn't be the only factor in deciding whether to use these powerful drugs. The Medicare GLP-1 Bridge program will offer semaglutide (Wegovy), tirzepatide (Zepbound), and orforglipron (Foundayo) for $50 per month through the end of 2027, potentially opening doors for an estimated 3.8 million eligible seniors.

Who Qualifies for the Medicare GLP-1 Bridge Program?

To access the program, you must meet specific criteria set by the Centers for Medicare and Medicaid Services. The eligibility requirements focus on body mass index (BMI), a measurement of weight relative to height, and existing health conditions linked to obesity.

• BMI of 35 or higher: This threshold represents severe obesity, roughly equivalent to 245 pounds for someone 5'10" tall.
• BMI between 27 and 34.9 with complications: You qualify if your BMI falls in this range and you have at least one obesity-related health condition, such as heart disease, diabetes, arthritis, or sleep apnea.
• Medicare Part D enrollment: You must be enrolled in an eligible Part D prescription drug plan, either through original Medicare or a Medicare Advantage plan with drug coverage.
• Age requirement: You must be 18 or older, though the program is primarily designed for older adults.

It's important to note that the $50 copay does not count toward your Part D deductible or the annual out-of-pocket spending limit, and it's not eligible for the Medicare Prescription Payment Plan, which normally allows beneficiaries to spread costs throughout the year.

How Well Do These Medications Work for Older Adults?

One of the most encouraging findings for seniors considering these medications is that they appear to work just as effectively in people over 65 as they do in younger adults. Recent research has provided solid evidence on this front. A study of 358 adults aged 65 and older who took semaglutide found they lost an average of 15.5% of their body weight, compared to 15.6% for younger adults in the same trials. Those who received a placebo injection lost only 5% of their body weight on average.

Results were similarly impressive for tirzepatide. An analysis of seven randomized controlled trials focusing on adults over 65 showed that seniors on the highest dose lost about 23.3% of their starting weight, while younger adults lost about 22.6%. Placebo groups lost between 2% and 4%. A separate analysis of 64 studies by researchers at Johns Hopkins Bloomberg School of Public Health reached the same conclusion: the benefits are consistent regardless of age.

However, experts emphasize that these findings come with an important caveat. The clinical trials included relatively small numbers of older participants, particularly those over 75. Across semaglutide studies, only 358 participants were 65 or older, with 100 of those in the placebo group. Tirzepatide trials included 575 adults over 65 without type 2 diabetes and 351 with diabetes.

"When you look at the trials, most trials either exclude older adults, or if they include them, very few are over the age of 65, and even fewer are over the age of 75," said Dr. John Batsis, a geriatrician and nutritionist at the University of North Carolina's Gillings School of Public Health.

Dr. John Batsis, Geriatrician and Nutritionist at University of North Carolina's Gillings School of Public Health

What Risks Should Older Adults Consider?

While the weight-loss results are promising, older adults face some unique considerations. One concern is that weight loss on these medications may include muscle loss, not just fat loss, which could affect balance and increase fracture risk in seniors. Resistance exercise or weightlifting becomes essential while using these drugs to preserve muscle mass.

Older adults also experienced more side effects in clinical trials compared to younger participants. In tirzepatide studies, seniors were about twice as likely as younger adults to stop taking the medication due to adverse events. Gastrointestinal side effects were cited by 7% of participants as their reason for discontinuing the drug, and about 1 in 4 seniors using tirzepatide experienced nausea.

"Being obese is never healthy, and if these drugs help people lose weight, that's a great thing. But I think we just have to think about what are some of the other potential problems that could arise from these drugs," said Dr. Jennifer Schrack, who directs the Center for Aging and Health at Johns Hopkins Bloomberg School of Public Health.

Dr. Jennifer Schrack, Director of the Center for Aging and Health at Johns Hopkins Bloomberg School of Public Health

How to Prepare If You're Considering These Medications

• Consult your healthcare provider: Have a detailed conversation with your doctor about whether these medications are appropriate for your specific health situation, existing conditions, and medications you're taking.
• Plan for exercise: If you start one of these medications, commit to a resistance training program to help preserve muscle mass during weight loss and maintain strength and balance.
• Understand the program logistics: Work with your provider and pharmacist to navigate the enrollment process, as the program operates outside standard Part D coverage and may involve additional administrative steps.
• Monitor side effects: Be aware of potential gastrointestinal side effects and discuss with your doctor how to manage them if they occur.

The Real-World Impact: One Senior's Success Story

For Barbara Senich, 69, the combination of medications including Zepbound has been transformative. After struggling with obesity for most of her life, losing and regaining weight multiple times, and even undergoing bariatric surgery that didn't provide lasting results, she finally found stability. She now weighs 137 pounds, a number she hadn't seen since her teenage years, and has been able to maintain that weight for about five years.

"This is the thing that's been the miracle for me, is the maintenance," Senich said. However, she has had to pay out of pocket for Zepbound since her Medicare drug plan doesn't cover weight-loss medications. The new bridge program could change that reality for millions of seniors like her.

Why Medicare Is Funding This Experiment

By law, Medicare cannot cover medications used solely for weight loss. However, obesity is a major driver of many diseases common in aging, including heart disease, cancer, dementia, arthritis, and diabetes. The Centers for Medicare and Medicaid Services is piloting this program to test whether these medications might ultimately save the program money and improve health outcomes. The program will run through December 2027.

Rates of obesity in older adults have roughly doubled between 1988-94 and 2015-18, according to the Population Reference Bureau. Today, about 2 out of every 5 seniors is obese based on their BMI. Even modest weight loss can improve risks for these age-related diseases, which is why the potential impact of this program could be significant.

As the program rolls out, both patients and providers will need clear information about how to access it. The program will be administered by Humana, which will process claims and handle prior authorization requests, but the administrative complexity means that outreach and education will be critical to ensuring eligible seniors can actually access these medications.